Are you saying therefore that if we were to engage say Acadia for eg as a partner to conduct Ph III trials in the USA and with marketing rights for 2591 for Phelan McDermid syndrome, they'd require us to licence them for the other 3 indications as well? So it would be all or nothing kind of deal?
Granting marketing rights for NNZ-2591 in PMS to Acadia would likely be highly problematic, in my opinion.
Firstly, as you suggested, Acadia would almost certainly want to tie up the other indications as well.
Secondly, the competitive interest in and potential value of Neuren would be greatly diminished.
Finally, if Acadia did tie up the other NNZ-2591 indications, it might as well acquire the company.
My thinking is that Acadia wouldn’t want to pay anything approaching the expectations of the takeover supporters here - and with competitive interest removed from the equation, why would they? Thus the takeover supporters would be disappointed.
I also don’t think that Acadia has the heft to run multiple trials of NNZ-2591 concurrently and quickly put in place a global marketing strategy. Hence, those in favour of seeing NNZ-2591 take the fastest route to market for multiple indications for the benefit of the patients would also be disappointed.
Finally, such an outcome would also disappoint those who want to see Neuren grow to become a powerhouse pharma in its own right.
Once again, I am not an expert in these matters, and this is just my opinion.
NEU Price at posting:
$25.11 Sentiment: Hold Disclosure: Held
(20min delay)